GlassScriptPhysician profile
Monina S Cabrera
NPI 1407821150
$1,553.52
in general payments reported to CMS, 2019-2025
23 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $13.71 · 2021: $126 · 2022: $245 · 2023: $369 · 2024: $217 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.63 | 2019-2025 | Sogroya |
| Abbott Laboratories | $160.99 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $144.69 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $144.24 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $139.18 | 2022-2023 | |
| Beta Bionics, INC. | $131.85 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $81.17 | 2019-2023 | Lupron Depot |
| Dexcom, INC. | $76.45 | 2019-2023 | Dexcom G6 Transmitter |
| Tolmar Pharmaceuticals, INC. | $72.99 | 2021 | |
| Nestle Healthcare Nutrition INC. | $68.38 | 2023 | |
| Lilly USA, LLC | $50.51 | 2019-2023 | Lyumjev, Baqsimi |
| Medtronic, INC. | $35.17 | 2023-2024 | Minimed 780g |
| Biomarin Pharmaceutical INC. | $31.38 | 2022 | |
| Sequel Med Tech, LLC | $30.22 | 2025 | Twiist |
| Arbor Pharmaceuticals, INC. | $25.67 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $21.84 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.03 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $19.51 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.12 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $14.40 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $13.76 | 2019 | |
| Lifescan, INC. | $12.51 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monina Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.